Indivior PLC (INDV)
NASDAQ:INDV
Want to see INDV full AI Analyst Report?
INDV Stock Chart & Stats
$32.70
--
Market closed
$32.70
--
Day’s Range― - ―
52-Week Range$10.63 - $40.02
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.98M
Market Cap
$4.59B
Enterprise Value$5.03B
Total Cash (Recent Filing)$175.00M
Total Debt (Recent Filing)$509.00M
Price to Earnings (P/E)10.7
Beta0.65
Next Earnings
Jul 23, 2026EPS Estimate
0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.96
Shares Outstanding121,922,060
10 Day Avg. Volume1,437,354
30 Day Avg. Volume2,980,914
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-45.77
Price to Sales (P/S)3.62
P/FCF Ratio-48.23
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue3.90
Enterprise Value/Gross Profit4.69
Enterprise Value/Ebitda11.13
Forecast
1Y Price Target
$50.67Price Target Upside54.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)3.13
Revenue Forecast (FY)$1.16B
Bulls Say, Bears Say
Bulls Say
SUBLOCADE Commercial MomentumSUBLOCADE's double-digit revenue and dispense-unit growth reflect durable demand for a monthly injectable OUD therapy. Recurring monthly administration, rising new patient starts and prescriber expansion support predictable, multi-quarter revenue and cash generation for the core franchise.
High Margins And Improved ProfitabilitySustained high gross margins and a meaningful net margin turnaround indicate structural product economics and pricing power. Combined with demonstrated operating leverage and management guidance for much higher adjusted EBITDA margins, this supports durable cash conversion if working-capital trends normalize.
Capital Structure Improvement Via Low-cost RefinancingRefinancing materially reduces interest expense and replaces higher-cost bank debt with flexible convertibles, lowering near-term cash interest and covenant risk. Projected sub-1x leverage plus remaining buyback capacity indicate improving financial flexibility for operations and strategic options.
Bears Say
Negative Shareholders' EquityNegative equity is a material, persistent balance-sheet weakness that constrains financial flexibility, may complicate access to certain capital markets, and can impair stakeholder confidence. It also skews leverage metrics and limits cushion against operational shocks.
Weak Recent Cash GenerationNegative operating and free cash flow despite profitability suggest working-capital or timing issues and reduce runway for organic R&D, commercialization investments, or continued buybacks. Sustained cash conversion weakness raises refinancing and liquidity risk absent improvement.
Concentration Risk And Pipeline SetbacksHeavy dependence on one product for growth makes revenues sensitive to gross-to-net swings, payer dynamics, dispense yields, competitive entrants, and patent timing. Recent decisions to halt internal progression of key programs weaken medium-term pipeline diversification.
Indivior News
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $10.63 and its highest was $40.02 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $4.59B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Jul 23, 2026 which is in 80 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Apr 30, 2026. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.3.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.83.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 121,922,060 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $0.96 in its last earnings report, beating expectations of $0.66. Following the earnings report the stock price went up 7.701%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in INDV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.67 (54.94% Upside)
$50.67 (54.94% Upside)
Blogger Sentiment
Bullish
INDV Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $31.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
262.93%
12-Months-Change
Fundamentals
Return on Equity
-98.94%
Trailing 12-Months
Asset Growth
-9.13%
Trailing 12-Months
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
INDV Company Deck
INDV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution and substantial financial improvement driven by SUBLOCADE (double-digit revenue growth, 20% dispense unit growth, record adjusted EBITDA up 112% and raised 2026 guidance). It also announced disciplined capital actions that improve the balance sheet and return capital to shareholders. Offsetting these positives were setbacks in early-stage R&D (INDV-6001 and INDV-2000 not advancing internally), expected gross-to-net pressure for 2026, and ongoing reliance on SUBLOCADE for growth. On balance, the favorable commercial and financial momentum and upgraded guidance materially outweigh the program setbacks and known headwinds.View all INDV earnings summariesINDV Stock 12 Month Forecast
Average Price Target
$50.67
▲(54.94% Upside)
Technical Analysis
Neurocrine
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
0.78% Insiders
6.81% Mutual Funds
0.85% Other Institutional Investors
64.99% Public Companies and Individual Investors